Efficacy and safety of mizoribine for patients with Sjogren's syndrome in pediatric age
Phase 2
- Conditions
- Sjogren's syndrome in pediatric age
- Registration Number
- JPRN-UMIN000004237
- Lead Sponsor
- Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with a history of mizoribine use 2.Patients with a white blood cell count of not more than 3,000 / mm3 3.Pregnant women or women who may become pregnant and women who wish to become pregnant during the course of the study 4.Patients who used cevimeline hydrochloride hydrate, pilocarpine hydrochloride and anetholtrithion within the 4 week period before the start of the study 5.Patients using other immunosuppressive drugs and anti-rheumatoid drugs 6.Other patients who were judged to be ineligible for the study by an attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of saliva production Change of data of laboratory examinations
- Secondary Outcome Measures
Name Time Method Change of salivary function, change of subjective symptoms, change of data of laboratory examinations, gastrointestinal symptoms